SyntekaBio Valuation
Is A226330 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of A226330 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate A226330's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate A226330's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A226330?
Key metric: As A226330 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.
| What is A226330's PB Ratio? | |
|---|---|
| PB Ratio | 3.1x |
| Book | ₩31.63b |
| Market Cap | ₩97.96b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 685.3x |
| Enterprise Value/EBITDA | -7.9x |
| PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does A226330's PB Ratio compare to its peers?
| Company | Forward PB | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 3.2x | ||
A384470 Coreline Soft | 8.1x | n/a | ₩90.6b |
A071200 INFINITT Healthcare | 0.7x | n/a | ₩109.2b |
A099750 ezCaretech | 3x | n/a | ₩110.7b |
A032850 BIT Computer | 1.1x | n/a | ₩78.2b |
A226330 SyntekaBio | 3.1x | n/a | ₩98.0b |
Price-To-Book vs Peers: A226330 is good value based on its Price-To-Book Ratio (3.1x) compared to the peer average (3.2x).
Price to Book Ratio vs Industry
How does A226330's PB Ratio compare vs other companies in the Asian Healthcare Services Industry?
| 1 Company | Price / Book | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Book vs Industry: A226330 is expensive based on its Price-To-Book Ratio (3.1x) compared to the Asian Healthcare Services industry average (2.8x).
Price to Book Ratio vs Fair Ratio
What is A226330's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PB Ratio | 3.1x |
| Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate A226330's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Access Bio
₩188.3b
Engages in the research, development, and manufacture of in vitro rapid diagnostic tests, biosensors, and molecular diagnostic products worldwide.
A950130
₩5,570.00
7D
2.0%
1Y
-37.1%
Vieworks
₩192.8b
Develops, manufactures, and sells imaging systems and solutions.
A100120
₩21,000.00
7D
3.4%
1Y
-24.2%
Wonbiogen
₩43.5b
Develops and sells medical equipment in South Korea.
A307280
₩1,225.00
7D
-1.1%
1Y
-21.6%